Dihexa for PoTS (Postural Orthostatic Tachycardia Syndrome) Brain Fog: Cerebral Hypoperfusion, the 2025 Adelaide SPECT Study, the Post-COVID Surge & the UK PoTS Care Crisis (2026 UK Review)

Postural orthostatic tachycardia syndrome (PoTS) is now one of the fastest-growing diagnoses in UK autonomic medicine, and one of the most cognitively disabling. A 2025 European Heart Journal analysis by Dulal, Grubb and Maraey of more than 65 million patient records reported a roughly 14-fold rise in PoTS incidence post-pandemic, while a 2025 Circulation: Arrhythmia and Electrophysiology paper found that ~31% of highly symptomatic Long COVID patients meet PoTS criteria. Around 80–85% of patients are female, typically between 15 and 50, and patient surveys consistently report brain fog as one of the most disabling symptoms — forgetfulness (91%), difficulty thinking (89%), difficulty focusing (88%) on Ross/Stewart cohort data. The biology is increasingly tractable: the January 2025 Scientific Reports brain SPECT paper by Seeley et al. at the University of Adelaide's Australian Dysautonomia and Arrhythmia Research Collaborative documented abnormal regional cerebral perfusion in PoTS patients with cognitive dysfunction, joining Stewart's transcranial Doppler work and Wells' neuropsychological data as objective evidence that PoTS brain fog has a measurable haemodynamic substrate. That biology converges on reduced cerebral blood flow, sympathetic hyperarousal and impaired hippocampal BDNF signalling — the same downstream endpoint that Dihexa, a positive modulator of HGF/c-Met synaptogenesis with documented cerebrovascular effects, also reaches. Against that backdrop sits the UK PoTS care crisis: the October 2024 Westminster Hall debate led by Cat Smith MP and PoTS UK's Parliamentary Campaign 2025, the absence of a NICE PoTS guideline, off-licence ivabradine prescribing and a 4–7 year diagnostic delay for many patients. This 2026 UK review walks through PoTS subtypes, the cerebral hypoperfusion case, the BDNF-HGF-c-Met chain, the evidence hierarchy — with structured autonomic care first and unlicensed peptides essentially last.

PoTS in the UK in 2026: A Diagnosis on a Steep Curve

Postural orthostatic tachycardia syndrome (PoTS) is a form of chronic orthostatic intolerance defined by a sustained heart rate rise of at least 30 bpm (or to over 120 bpm) within 10 minutes of standing, in the absence of orthostatic hypotension, persisting for at least three months and producing chronic symptoms of orthostatic intolerance. For paediatric patients aged 12–19, the threshold is ≥40 bpm. The definition is on the PoTS UK clinician page and aligns with the 2015 Heart Rhythm Society Expert Consensus Statement by Sheldon and colleagues.

UK epidemiology is harder to pin down than acute Lyme or hypothyroidism for a structural reason: there is no NICE guideline, no national PoTS registry and no ICD-10 code dedicated to the syndrome (it sits under R00.0 sinus tachycardia or G90.9 autonomic dysfunction). The most quoted UK figure of ~170 in 100,000 derives from international estimates pre-pandemic. PoTS UK — the patient-and-clinician charity led by Trudie Lobban and Dr Lesley Kavi — estimates several hundred thousand UK adults are affected, with 80–85% female. McDonald, Koshi, Busner, Kavi and Newton's 2014 BMJ Open paper remains the foundational UK perspective.

What changed everything is the post-pandemic surge. The Dulal, Grubb and Maraey 2025 European Heart Journal analysis of more than 65 million patient records reported PoTS incidence rising roughly 14-fold compared with pre-pandemic baseline, driven dominantly by post-COVID autonomic dysfunction. A 2025 Circulation: Arrhythmia and Electrophysiology paper by Larsen and colleagues following 467 highly symptomatic Long COVID patients found that 31% met PoTS criteria and another 27% had partial features — with 42% having no PoTS phenotype. The LISTEN study in JACC: Advances (2025) confirmed the same pattern in a separate cohort, and an October 2025 JACC paper using quantitative autonomic testing put autonomic dysfunction among the most prevalent objectively measurable abnormalities in Long COVID.

The UK service backdrop has not kept pace. The October 2024 Westminster Hall debate led by Cat Smith MP (Labour, Lancaster and Wyre) heard cross-party testimony that PoTS patients are "falling through the cracks" of a healthcare system unprepared to recognise or support them. PoTS UK met with Sharon Hodgson MP (Parliamentary Under-Secretary for Public Health) and the Department of Health and Social Care to press for a NICE referral, ICB-level commissioning standards and protected specialist clinics. As of June 2026, no NICE PoTS guideline has been published, and existing specialist clinics — UCLH Autonomic Unit, the Royal Brompton, Newcastle Falls and Syncope Service, Cardiff and Sheffield centres — remain oversubscribed.

Against that backdrop, the patient-facing question is familiar from Long COVID, ME/CFS and fibromyalgia: "I can describe my symptoms accurately, my heart rate is documented, the cognitive impairment is real — do unlicensed compounds like Dihexa belong anywhere in the conversation?" This article takes the question seriously: does the science support the step, or is the answer the unglamorous one that gets the best evidence base?

PoTS Subtypes and Why They Matter for Brain Fog

PoTS is increasingly understood not as a single disease but as a final common pathway shared by several distinct pathophysiologies. The Vanderbilt Autonomic Dysfunction Center framework recognises overlapping subtypes. Subtype matters because cognitive-symptom mechanism, first-line treatment and theoretical Dihexa risk profile all change between them.

Neuropathic PoTS

Characterised by partial peripheral autonomic denervation, particularly in the lower limbs, with reduced sympathetic vasoconstriction on standing. Small fibre neuropathy is found in a subset on skin biopsy. The orthostatic phenotype is driven by venous pooling and reflex tachycardia. Brain fog in this subtype tracks cerebral hypoperfusion most cleanly — cognitive symptoms map onto the magnitude of the postural fall in cerebral blood flow on transcranial Doppler.

Hyperadrenergic PoTS

Driven by elevated standing noradrenaline (≥600 pg/mL on the classical Vanderbilt threshold) and prominent sympathetic activation symptoms — tremor, anxiety, hypertension on standing, sweating, vivid stress responses. Approximately 10% of PoTS cohorts overall but a higher proportion of patients who present with prominent psychiatric features. Brain fog in this subtype intermingles with sympathetic hyperarousal: the 2022 Brain fog in neuropathic PoTS paper showed brain fog correlates with autonomic hyperarousal and improves after water drinking — consistent with both haemodynamic and adrenergic drivers.

Hypovolaemic PoTS

A subset of patients show reduced plasma volume (often 13–30% below normal) and abnormally low standing renin/aldosterone responses. Volume expansion with salt and fluids is particularly effective here. Cognitive symptoms respond to volume status almost in real time.

PoTS with Mast Cell Activation Syndrome (MCAS)

A clinically important overlap. The 2005 Shibao et al. Hypertension paper from Vanderbilt established that mast cells can pair with autonomic nerve fibres and histamine directly stimulates noradrenaline release. The result is a positive-feedback loop: mast cell degranulation releases histamine and vasoactive mediators, vasodilation triggers reflex sympathetic activation, noradrenaline rises, orthostatic intolerance worsens, mast cell activity escalates. Brain fog in this subtype overlays a histamine-driven component.

PoTS with Hypermobile Ehlers-Danlos / Hypermobility Spectrum Disorder

Joint hypermobility is over-represented in PoTS cohorts. The recent Cureus hypermobility palpitations/dizziness/syncope paper highlights joint hypermobility as an under-recognised cause of orthostatic symptoms in young females. Mechanism is debated — abnormal connective-tissue venous compliance and small fibre neuropathy both contribute. Brain fog in this subtype frequently coexists with chronic pain.

Secondary PoTS

An important rule-out. Diabetic autonomic neuropathy, paraneoplastic syndromes (anti-ganglionic AChR antibody disease), amyloid neuropathy, post-viral PoTS, deconditioning following prolonged bedrest, and a long list of drug effects can produce the same phenotype. Diagnostic vigilance matters because Dihexa is not a treatment for any of these — and would mask the symptom signal that should trigger appropriate workup.

The clinical takeaway: the question "does Dihexa help PoTS brain fog?" is not a single question. It is a different question in neuropathic PoTS (haemodynamic-cognitive coupling), hyperadrenergic PoTS (sympathetic hyperarousal with potential noradrenergic destabilisation risk), MCAS-overlap PoTS (histaminergic axis added), and EDS-overlap PoTS (chronic pain and dysautonomia interaction). Mechanism-first reasoning gets weaker as the phenotype gets more complex.

The 2026 Biology of PoTS Brain Fog

PoTS-related cognitive dysfunction has moved firmly out of the "medically unexplained" category in the last five years. The dominant biological themes are cerebral hypoperfusion, autonomic hyperarousal, sleep fragmentation and downstream hippocampal BDNF reduction.

Cerebral Hypoperfusion and Cerebral Blood Flow Reactivity

Stewart and colleagues' 2020 Frontiers in Neuroscience paper documented reduced middle cerebral artery blood flow velocity during sustained cognitive stress in PoTS patients, even in the seated position — that is, independently of orthostatic stress. The implication is critical: PoTS brain fog is not just a "I stood up and felt dizzy" phenomenon. Cognitive performance and cerebral blood flow are both reduced under sustained mental load, suggesting an impaired ability to up-regulate cerebral perfusion to meet cognitive demand.

The Journal of the American Heart Association companion paper by the same group reinforced the cerebral-perfusion-cognition link and added an autonomic-reactivity dimension. The POTSKog study (Clinical Autonomic Research, 2023) showed cognitive performance varied with body position, confirming postural sensitivity.

The 2025 Adelaide SPECT Study

The most important imaging advance is the January 2025 Scientific Reports paper by Seeley et al. at the University of Adelaide's Australian Dysautonomia and Arrhythmia Research Collaborative. Using brain single-photon emission computed tomography (SPECT), the team documented abnormal regional cerebral perfusion patterns in PoTS patients with cognitive dysfunction, compared with controls. The imaging signal added an objective, regionally specific perfusion abnormality to the haemodynamic story — consistent with Stewart's transcranial Doppler work but with anatomical resolution. The paper has been one of the most influential PoTS publications in the cognitive-symptom literature in five years, and it is the cleanest current evidence that PoTS brain fog is a treatable biological phenomenon rather than a psychosomatic complaint.

Autonomic Hyperarousal and Noradrenergic Drive

Elevated standing noradrenaline (the defining feature of the hyperadrenergic subtype but elevated to a lesser degree across PoTS more broadly) drives sympathetic hyperarousal, vigilance and anxiety symptoms that overlay cognitive performance independently of cerebral blood flow. The Wells et al. 2017 Autonomic Neuroscience review details the cognitive-psychological pattern: working memory and attention are most affected, with executive function and processing speed following.

Sleep Fragmentation

PoTS sleep is rarely intact. Sympathetic hyperarousal, palpitations, restless legs, anxiety and frequent nocturia (driven by recumbent natriuresis after daytime fluid pooling) all fragment sleep. Reduced slow-wave and REM sleep independently impair cognitive performance and lower hippocampal BDNF expression. The PoTS brain-fog signal cannot be cleanly separated from the sleep-fragmentation signal in most patients. See Dihexa for sleep and memory consolidation for the underlying biology.

Hippocampal BDNF and Synaptic Plasticity in Chronic Hypoperfusion

Chronic cerebral hypoperfusion — whether driven by carotid disease, vascular cognitive impairment or autonomic insufficiency — reduces hippocampal BDNF expression and impairs CA1 long-term potentiation in animal models. The end-state in PoTS overlaps with the end-state in vascular dementia and post-stroke cognitive impairment: reduced BDNF-TrkB signalling at the synapse, driven by an upstream haemodynamic problem.

Mast Cell and Cytokine Axis (MCAS Subset)

Histamine, prostaglandins, tryptase and other mast cell mediators have direct CNS effects on attention, sleep and mood. In MCAS-overlap PoTS, the brain-fog signal carries an inflammatory component that overlaps mechanistically with Long COVID brain fog and fibromyalgia fibro fog.

The BDNF-HGF-c-Met Chain: Where Dihexa Enters the Picture

For the Dihexa-specific question, the most relevant molecular story is the three-way link between hippocampal BDNF, the HGF/c-Met system, and cerebrovascular biology. Each of these influences synaptic plasticity, and HGF/c-Met has an additional documented role in cerebrovascular angiogenesis and blood-brain barrier integrity — an unusual feature in the procognitive-mechanism space and one that maps onto the PoTS haemodynamic problem.

Hippocampal BDNF, released in an activity-dependent fashion, binds TrkB and drives dendritic spine maturation, LTP, and long-term cognitive plasticity. Independently, HGF/c-Met signalling drives synaptogenesis through the PI-3K/AKT and MAPK pathways — a parallel track that converges on the same cellular outcome. A 2021 Frontiers in Cell and Developmental Biology review details how MET expression in cortex sustains adult synaptogenesis and angiogenesis. The cerebrovascular angle is particularly relevant in PoTS: c-Met activation supports endothelial integrity, capillary remodelling and blood-brain barrier function — the cellular substrate of the perfusion abnormality the Adelaide SPECT study documented.

Dihexa — a small-molecule peptide analogue derived from angiotensin IV — is a positive modulator of the HGF/c-Met pathway. Full molecular detail is on the mechanism of action page. The relevance to PoTS brain fog rests on three points of overlap:

• Synaptogenesis as a parallel route to hippocampal plasticity. When BDNF expression is suppressed by chronic hypoperfusion and sympathetic hyperarousal, an upstream pathway that pushes synaptogenesis from a different signalling axis is conceptually interesting. The operative word is conceptually; the clinical data to back up that reasoning in PoTS do not exist.
• Cerebrovascular angiogenesis as a parallel route to perfusion. Unlike most procognitive mechanisms, HGF/c-Met has a documented cerebrovascular component — capillary network density, endothelial integrity and BBB function. In a syndrome whose cardinal cognitive substrate is reduced cerebral blood flow under load, this is a more anatomically targeted mechanism than most. The catch, as always, is that mechanism is not evidence.
• Regional c-Met expression maps onto the PoTS cognitive deficit. The hippocampus, prefrontal cortex and anterior cingulate — regions affected by the working memory, attention and executive function deficits PoTS patients describe — are among those with the highest density of c-Met receptors in the adult brain.

This is the mechanistic case for considering Dihexa in PoTS. The rest of this article is about why the shape of the mechanism is not the same as evidence for the intervention — and why the autonomic, haemodynamic and (in the hyperadrenergic subtype) noradrenergic context limit how confidently a synaptogenic peptide can be expected to deliver sustained cognitive benefit.

Structured PoTS Care First: The Only Evidence-Based Starting Point

Any honest review of PoTS-related cognitive symptoms has to begin with the structured first-line pathway, because the evidence base for non-pharmacological measures is substantially stronger than for anything else. PoTS UK and the HRS Expert Consensus Statement agree on the basic structure.

• Make the diagnosis with a structured stand or tilt test. The PoTS UK diagnostic criteria set out the 10-minute active stand or head-up tilt protocol. Holter monitoring, echocardiography, supine and standing catecholamines, autonomic function testing and screening for treatable causes (TSH, FBC, ferritin, B12, fasting glucose, U&E, anti-ganglionic AChR antibodies in atypical presentations) are appropriate next steps.
• Salt and fluids. 8–10 g of sodium chloride daily (about 1.5–2 teaspoons), 2–3 litres of fluid. Slow sodium tablets can help in hypovolaemic phenotypes. Contraindicated in heart failure, uncontrolled hypertension and some renal disease.
• Compression garments. Class 2 (20–30 mmHg) full-length compression hosiery or abdominal binders. Abdominal compression has the strongest evidence for reducing splanchnic pooling.
• Graded exercise reconditioning. The Levine/CHOP modified Dallas protocol — recumbent rowing, recumbent cycling, swimming and supine resistance training for 3–8 months before progressing to upright work — has the strongest published evidence of any intervention in PoTS, with roughly 50–70% of compliant patients showing meaningful improvement.
• Sleep and triggers. Head-of-bed elevation by 15–30°, avoidance of prolonged supine inactivity, careful heat management, structured pacing and trigger identification. Caffeine and alcohol are individually variable but frequently destabilising.
• Pharmacology under specialist supervision. Ivabradine (off-licence under NHS specialist supervision; covered in detail below), low-dose propranolol (10–20 mg, often four times daily), bisoprolol, midodrine, fludrocortisone (often 50–100 mcg/day), pyridostigmine and (rarely) octreotide or IV saline. Drug choice is phenotype-driven.
• Comorbidity management. MCAS treatment with H1 and H2 antihistamines and cromolyn where indicated; ME/CFS pacing strategies where post-exertional malaise is prominent; hypermobile EDS / hypermobility spectrum disorder management; iron deficiency correction; treatment of OSA (see OSA review) and depression / anxiety where present.

For UK patients with PoTS-related cognitive symptoms, the right starting point is a structured autonomic assessment with a PoTS-literate clinician, a six-month trial of the non-pharmacological first-line package above, and a frank discussion of pharmacological options if symptoms remain disabling. Experimental peptides are not a substitute for that pathway.

Ivabradine, Beta-Blockers and the UK Pharmacological Picture in 2026

Ivabradine — an Iₛ inhibitor that selectively slows the sino-atrial node without affecting blood pressure or sympathetic tone — has become one of the most useful PoTS pharmacological tools in UK clinical practice. The published evidence base is modest (small RCTs, observational cohorts), but mechanism and clinical impression have driven uptake. The licensed UK indications under NICE TA679 are chronic heart failure and chronic stable angina; use in PoTS is off-licence, requires specialist initiation and informed consent, and is variably supported by Integrated Care Boards. The Lancashire and South Cumbria New Medicine Assessment is a representative ICB-level review.

The December 2025 Journal of Cardiovascular Pharmacology review covered by the ME Association consolidated the case: ivabradine reduces standing heart rate, improves symptoms in a meaningful minority and may be particularly useful where beta-blockade is poorly tolerated. Low-dose propranolol remains widely used and has the advantage of also dampening the sympathetic hyperarousal component of brain fog.

The relevance to the Dihexa question is twofold. First, ivabradine and beta-blockers are licensed, prescribed, evidence-supported options that should be considered before any unlicensed peptide. Second, ivabradine's mechanism is haemodynamic, not synaptogenic — it addresses the upstream driver of cognitive symptoms (cerebral perfusion under load), where Dihexa addresses a downstream plasticity endpoint. From a pure systems-biology perspective, an upstream haemodynamic intervention has a stronger case in PoTS than a downstream synaptogenic one.

PoTS-Specific Risks of Dihexa Use in This Population

The general Dihexa safety discussion is on the side effects and risks page. Several risks become more pointed in the context of a haemodynamic-autonomic disorder.

Hyperadrenergic Subtype and Noradrenergic Destabilisation

The hyperadrenergic phenotype (standing noradrenaline ≥600 pg/mL, prominent sympathetic activation symptoms) is a particular concern. Dihexa's effects on central noradrenergic tone in chronically hyperadrenergic patients have not been characterised. Anecdotal reports of vivid dreams, sleep disturbance and (in a minority) anxiety on Dihexa overlap unhelpfully with the hyperadrenergic PoTS symptom profile. Any worsening of palpitations, tremor, anxiety, sleep disturbance or sympathetic symptoms in the first week of a trial should be treated as a stop signal.

MCAS and Mast Cell Destabilisation

Dihexa's interaction with the mast cell axis is not characterised. In MCAS-overlap PoTS, adding an unlicensed peptide of unknown mast cell pharmacology to an already destabilised mediator system is biologically incoherent and clinically risky. Patients with documented MCAS should not consider Dihexa.

Masking Treatable Contributors

The recurring risk across infection-associated and chronic illness contexts. A non-specific lift in perceived cognitive clarity from an unlicensed compound can delay the structured autonomic workup that should identify hypovolaemia, iron deficiency, vitamin D and B12 deficiency, hypothyroidism (see Hashimoto's review), OSA (see OSA review) and treatable secondary causes. These are correctable contributors that are NHS-fundable and safer than peptides.

Diagnostic Overshadowing

New focal neurological symptoms, syncope of unclear mechanism (versus the more characteristic PoTS pre-syncope), persistent chest pain, palpitation phenotypes outside the usual PoTS pattern or progressive cognitive decline all warrant fresh diagnostic workup regardless of an existing PoTS label. Adding an unlicensed peptide to the symptom picture complicates that workup.

Displacement of Exercise Reconditioning

The single intervention with the strongest evidence base in PoTS — structured graded exercise reconditioning — is demanding and slow to produce results. Patients who substitute a pharmacological "shortcut" (whether a licensed drug or an unlicensed peptide) for the reconditioning programme typically have worse long-term outcomes. Dihexa is not a substitute for exercise reconditioning.

Baseline Oncology Considerations

The general c-Met / oncology concern that applies to all Dihexa use applies here. Patients with a personal or family history of breast, ovarian, lung, gastric or other c-Met-relevant cancers should not consider Dihexa for any indication, including PoTS-related cognitive symptoms.

Strong Placebo Response and Symptom Variability

PoTS symptoms fluctuate dramatically with sleep, menstrual cycle, infection, heat, dehydration and stress. Placebo response rates in PoTS trials run 20–40% for cognitive and fatigue endpoints. Any uncontrolled self-trial of an unlicensed peptide at a symptom peak is structurally biased towards reading regression to the mean as treatment effect.

The Fosgonimeton Parallel and the Limits of Mechanism

Because no controlled human trial of Dihexa in PoTS exists, the most informative clinical-stage comparator is fosgonimeton (ATH-1017): a small-molecule positive modulator of the HGF/MET system developed by Athira Pharma. Fosgonimeton is not Dihexa, but it shares the core mechanism of amplifying HGF/c-Met signalling. The full story is on the dedicated fosgonimeton page.

The Phase 3 LIFT-AD trial in Alzheimer's disease reported out in 2024 and did not meet its primary cognitive endpoint. The programme was subsequently refocused. For PoTS the message is direct: a well-validated, well-tolerated, mechanistically coherent approach to HGF/MET failed to produce a measurable cognitive win in a clinical population with established hippocampal dysfunction. PoTS adds a further complication — the cognitive substrate is principally upstream (cerebral perfusion under load) rather than downstream (synaptogenic capacity). A synaptogenic mechanism in a perfusion-limited population has, if anything, an even narrower window to deliver a clinical signal.

Mechanism-first reasoning is seductive; clinical endpoints in cognition are humbling. The fosgonimeton parallel is the closest in-human evidence available for the HGF/c-Met axis. It is not a flat negative on Dihexa in PoTS, but it should temper expectations to a substantial degree.

Who Should Not Consider Dihexa for PoTS Brain Fog

• Anyone with hyperadrenergic PoTS phenotype or marked sympathetic hyperarousal — theoretical noradrenergic destabilisation risk is not characterised.
• Anyone with diagnosed or strongly suspected MCAS — mast cell axis pharmacology of Dihexa is not characterised.
• Anyone with suspected secondary PoTS (diabetic autonomic neuropathy, paraneoplastic syndromes, amyloid neuropathy) — specialist workup is required.
• Anyone with new focal neurological symptoms, syncope of unclear mechanism, progressive cognitive decline or atypical chest pain.
• Anyone who has not had a structured autonomic assessment with active stand or tilt testing and the basic blood workup.
• Anyone who has not implemented and adhered to the non-pharmacological first-line package (salt, fluids, compression, graded recumbent-first reconditioning) for a meaningful period.
• Anyone with a personal or family history of breast, ovarian, lung, gastric, thyroid or other c-Met-relevant cancers.
• Anyone pregnant, breastfeeding or planning conception.
• Anyone with a diagnosed bipolar or psychotic-spectrum condition.
• Anyone on multiple licensed medications (ivabradine, beta-blockers, midodrine, fludrocortisone, antihistamines, antidepressants) without clinician oversight of an unlicensed addition.
• Anyone whose cognitive symptoms have not been formally characterised — baseline cognitive assessment helps distinguish PoTS-related cognitive change from alternative diagnoses.

What the Evidence Actually Supports for PoTS Brain Fog in 2026

For balance — and because this is where most patients should start — here is what the 2026 evidence base genuinely supports for cognitive symptoms in PoTS.

• Structured autonomic assessment. Active stand or head-up tilt test with continuous HR/BP monitoring. Holter, echo, supine/standing catecholamines where indicated. Basic bloods (FBC, U&E, LFTs, TSH, ferritin, B12, folate, vitamin D, fasting glucose / HbA1c, coeliac antibodies). Autonomic function testing in atypical presentations. The PoTS UK pathway is the basis for this conversation.
• Non-pharmacological first-line. Salt 8–10 g/day, fluids 2–3 L/day, class 2 compression, abdominal binders, graded recumbent-first reconditioning (Levine/CHOP protocol). The exercise programme has the strongest published evidence in PoTS — nothing pharmacological matches it for sustained benefit.
• Pharmacological options under specialist supervision. Ivabradine (off-licence under specialist initiation), low-dose propranolol or bisoprolol, midodrine (in tachycardia-with-hypotension phenotype), fludrocortisone, pyridostigmine. Choice is phenotype-driven and benefits from PoTS-literate clinical input.
• Correction of deficiencies and comorbidity treatment. Iron, B12, folate, vitamin D, thyroid optimisation, coeliac screening, MCAS treatment where indicated, OSA assessment, and treatment of mood and sleep symptoms. See Dihexa for depression & mood and Dihexa for anxiety & chronic stress.
• Cognitive rehabilitation and pacing. Where post-exertional malaise overlaps with the PoTS phenotype (frequent in Long COVID PoTS and ME/CFS-overlap PoTS), pacing strategies are a starting point. External scaffolds, structured cognitive routines and cognitive rehabilitation programmes have replicated effect sizes for autonomic-related cognitive impairment.
• Vetted patient-facing resources. PoTS UK, the NHS PoTS overview, the Bristol BNSSG ICB Remedy resource, the ME Association PoTS survey results and the Chest Heart & Stroke Scotland PoTS factsheet.
• Long COVID pathway integration. For PoTS associated with Long COVID, referral into the NHS Long COVID clinic network where available and engagement with PoTS UK's Long COVID resources. See the Long COVID brain fog review.
• Spontaneous recovery context. Approximately 50% of PoTS patients improve substantially or recover within 1–3 years of diagnosis, particularly in post-viral phenotypes (PoTS UK). This natural-history pattern is structurally biased to inflate any short-term self-treatment "effect".

If Someone Were Considering It: Practical Realities

This section is descriptive, not prescriptive. There is no validated protocol for Dihexa in PoTS because there is no trial. What follows is what self-experimenters report and the realities they describe — with caveats that should temper any inference.

• No PoTS-specific dose. Community dosing ranges (covered in the Dihexa dosage guide) were derived from cognitive-enhancement use in healthy younger users. Pharmacokinetics and dose-response in PoTS populations — particularly in hypovolaemic, hyperadrenergic or MCAS-overlap phenotypes — are not characterised.
• Short trials with clear stop rules. Brief cycles with explicit symptom-tracking endpoints (standing HR diary, cognitive self-rating, sleep quality, post-exertional malaise) are generally preferred to open-ended use. See the Dihexa Review 2026 for community-reported cycling approaches.
• Avoid complex stacking. Adding Dihexa to an already complex PoTS regime (ivabradine, beta-blockers, midodrine, fludrocortisone, antihistamines, sleep aids, antidepressants) creates an interaction landscape that no one can interpret meaningfully. The general stacking guide cautions explicitly against complex combinations.
• Track and rule out placebo. PoTS symptoms fluctuate weekly with sleep, menstrual cycle, weather, dehydration and stress. Any intervention tried during a symptom-peak week looks effective in the subsequent normal-variance dip. Brief structured symptom diaries covering standing HR, sleep, mood, cognitive self-ratings, energy and post-exertional malaise are the minimum self-assessment rigour for an unlicensed peptide trial.
• Re-check baseline bloods. Before any trial: FBC, U&E, LFTs, TSH, ferritin, B12, folate, vitamin D, glucose / HbA1c, coeliac antibodies. After: repeat targeted bloods.
• Maintain non-pharmacological measures. Whatever else is tried, salt, fluids, compression, head-of-bed elevation and reconditioning should continue. They are not optional.
• Stop at the first adverse signal. New palpitations beyond baseline, syncope, mood destabilisation, sleep disruption beyond the first few nights, worsening fatigue or post-exertional malaise are all reasons to stop and seek clinical review.

None of this should be read as endorsement. The strongest practical advice for PoTS brain fog in 2026 is the same one that applies before any peptide conversation: complete structured autonomic assessment, fix the treatable contributors, implement and persist with the non-pharmacological first-line, and engage with specialist input for pharmacological options where indicated.

The Bottom Line in 2026

PoTS-related cognitive symptoms are real, biological and increasingly well-understood. The 2025 Adelaide SPECT study, Stewart's transcranial Doppler work, Wells's neuropsychological characterisation and the rapidly expanding Long COVID PoTS literature all converge on a picture of cerebral hypoperfusion, sympathetic hyperarousal and downstream hippocampal dysfunction driving the cognitive phenotype. The dominant first-line intervention — with by far the largest evidence base — is structured non-pharmacological care under PoTS UK and HRS Expert Consensus standards, with phenotype-driven pharmacological options under specialist supervision where symptoms remain disabling.

Dihexa, with its direct activation of the HGF/c-Met synaptogenesis pathway and its unusual cerebrovascular component, is one of the few small molecules whose mechanism plausibly addresses parts of the underlying biology. The catch is the same as in every other indication on this site: there is no published, registered clinical trial of Dihexa in any autonomic disorder. The closest clinical-stage relative (fosgonimeton) confirmed feasibility of HGF/MET modulation in humans but missed its Phase 3 cognitive endpoint — in a population whose biology overlaps with PoTS only at the downstream-plasticity end. Mechanistic plausibility is necessary but not sufficient.

For the majority of UK patients with PoTS-related brain fog, the honest reading of the 2026 evidence is this. Structured autonomic assessment first, non-pharmacological first-line second, phenotype-appropriate pharmacology under specialist supervision third, comorbidity treatment fourth, and research chemicals essentially last — if at all. With the post-COVID PoTS surge, the 2025 Adelaide SPECT data, the PoTS UK Parliamentary Campaign 2025 pushing for a NICE referral, and the Long COVID PoTS literature consolidating, UK PoTS medicine is in a moment of real momentum. Self-experimentation with unlicensed peptides is, if anything, harder to justify in this moment, not easier.

Frequently Asked Questions

Related Reading on Dihexa.co.uk

• Dihexa for Long COVID Brain Fog (2026) — the most overlapping phenotype; ~31% of highly symptomatic Long COVID patients meet PoTS criteria.
• Dihexa for ME/CFS (2026) — substantial overlap with PoTS at the autonomic and cognitive level.
• Dihexa for Fibromyalgia & Fibro Fog (2026) — central-sensitisation and chronic-pain overlap with PoTS and hypermobile EDS.
• Dihexa for Lyme Disease & PTLDS (2026) — post-infectious autonomic dysfunction is a recognised post-Lyme phenotype.
• Dihexa for Sleep Apnoea Brain Fog (2026) — OSA overlaps with the sleep fragmentation component of PoTS brain fog.
• Dihexa for Hashimoto's & Hypothyroid Brain Fog (2026) — thyroid disease is over-represented in PoTS and a key treatable contributor.
• Dihexa for Anxiety & Chronic Stress (2026) — sympathetic hyperarousal in hyperadrenergic PoTS overlaps the anxiety substrate.
• Dihexa for Depression & Mood — mood symptoms in chronic dysautonomia.
• Dihexa for Post-Stroke Recovery (2026) — the cerebral hypoperfusion comparator.
• Dihexa for Vascular Dementia (2026) — chronic hypoperfusion biology in another guise.
• Dihexa for MCI & Brain Aging (2026) — the longer-term cognitive trajectory context.
• Dihexa vs BDNF: What "10 Million Times More Potent" Actually Means — in-depth look at the BDNF mechanism claim.
• Dihexa Review 2026 — effects timeline, oral vs sublingual, cycling.
• Dihexa Stacking Guide — why most stacks need clinician oversight.
• Mechanism of Action — HGF/c-Met, PI-3K/AKT, dendritic spines, cerebrovascular angiogenesis.
• Side Effects & Risks — the general safety picture.
• UK Legal Status — where Dihexa sits in UK law and MHRA advertising rules.
• Fosgonimeton & Athira — the cautionary Phase 3 story.

External Authoritative Sources Cited

• Seeley MC et al. (Scientific Reports, 2025). Brain SPECT and cerebral perfusion in PoTS with cognitive dysfunction.
• Stewart JM et al. (Frontiers in Neuroscience, 2020). Brain fog in PoTS: cerebral blood flow and neurocognitive analysis.
• Stewart JM et al. (JAHA, 2020). Cerebral blood flow and cognitive performance in PoTS under sustained cognitive stress.
• Wells R et al. (Autonomic Neuroscience, 2017). Cognitive and psychological issues in PoTS.
• Ross AJ, Medow MS, Rowe PC, Stewart JM (Clinical Autonomic Research, 2013). What is brain fog? An evaluation of the symptom in PoTS.
• Larsen NW et al. (Circulation: Arrhythmia and Electrophysiology, 2025). Prevalence and clinical impact of PoTS in highly symptomatic Long COVID.
• Larsen NW et al. (JACC: Advances, 2025). PoTS in Long COVID: LISTEN study self-reported data.
• Association of Autonomic Dysfunction With Long COVID (JACC, October 2025).
• Sheldon RS et al. (Heart Rhythm Society Expert Consensus Statement, 2015). Diagnosis and treatment of PoTS, IST and vasovagal syncope.
• Shibao C et al. (Hypertension, 2005). Hyperadrenergic PoTS in mast cell activation disorders.
• POTSKog study (Clinical Autonomic Research, 2023). Cognitive functioning in PoTS by body position.
• Brain fog in neuropathic PoTS and autonomic hyperarousal (2022).
• McDonald C, Koshi S, Busner L, Kavi L, Newton JL (BMJ Open, 2014). PoTS in UK women.
• PoTS UK — UK PoTS charity.
• PoTS UK Parliamentary Campaign 2025.
• NHS — Postural Tachycardia Syndrome overview.
• Bristol BNSSG ICB Remedy PoTS pathway.
• ME Association — PoTS Survey Results.
• ME Association — Journal of Cardiovascular Pharmacology PoTS medication review (Dec 2025).
• Chest Heart & Stroke Scotland — PoTS factsheet.
• Desbonnet-Lauquin et al. (Frontiers, 2021). HGF and MET in brain development and neurological disorders.
• Benoist CC et al. (JPET, 2014). Dihexa procognitive effects via HGF/Met.
• NIH NINDS — Postural Tachycardia Syndrome (PoTS).